|Students at Sheffield|
Friday, 20 July 2018
Thursday, 19 July 2018
Our quick search for CEA’s published in June uncovered 52 articles. In the right-hand column of this blog is a CEA Archive, which includes our CEA search results by month. Below are those in our areas of interest.
- De Mil R, Guillaume E, Guittet L, Dejardin O, Bouvier V, Pornet C, et al. Cost-Effectiveness Analysis of a Navigation Program for Colorectal Cancer Screening to Reduce Social Health Inequalities: A French Cluster Randomized Controlled Trial. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2018;21(6):685-91.
- Leurent B, Gomes M, Carpenter JR. Missing data in trial-based cost-effectiveness analysis: An incomplete journey. Health economics. 2018;27(6):1024-40.
- McKay AJ, Hogan H, Humphries SE, Marks D, Ray KK, Miners A. Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis. Atherosclerosis. 2018.
Tuesday, 17 July 2018
Monday, 16 July 2018
HEDS have renewed their collaboration with The Centre for Health Economics (CHE) as part of The National Institute for Health Research new set of 13 NIHR Policy Research Units to undertake research to inform decision-making by government and arms-length bodies.
The £65 million investment over five years will ensure that the government and arms-length bodies have the best possible information and evidence available when making policy decisions about health and social care.
The 13 new NIHR units will provide both a long-term resource for policy research and a rapid-response service to provide evidence for emerging policy needs. The units, which are considered to be an exemplar of good practice in government, will also offer advice to policy makers and analysts on the evidence base and options for policy development.
The units will cover a range of specialisms and conditions, such as behavioural science, adult social care, older people and frailty, and cancer awareness, screening and early diagnosis.
Each university-based NIHR Policy Research Unit will host a multidisciplinary team of researchers from collaborating institutions, to create a critical mass of experts for research in priority areas for health and social care policy.
The units will work closely with the Department of Health and Social Care to determine priorities and provide evidence directly to the Secretary of State for Health, government departments and arms-length bodies, such as NHS England and Public Health England.
Examples of the types of research topics the units may undertake include how behavioural science can help maximise the impact of clinical consultations; how outcomes of social care services vary for different groups of people; and how social inequalities affect the uptake of cancer screening.
Professor Chris Whitty, Chief Scientific Adviser for the Department of Health and Social Care, said:
“Patients and the public deserve a healthcare system that is informed by the latest research and evidence. The NIHR Policy Research Units will make sure that Government decisions affecting our health and care are robust and evidence based.”
These new units, which will begin work in January 2019, join two existing units in mental health and obesity.
Thursday, 12 July 2018
Once again we explore what new publications have been produced by HEDS in collaboration with colleagues in ScHARR. Many of these are currently in press, so you can find much of our work in its open access form via our institutional repository. Tuck in here.
Addison, M., Mcgovern, R., Angus, C., Becker, F., Brennan, A., Brown, H., Coulton, S., Crowe, L., Gilvarry, E., Hickman, M., Howel, D., Mccoll, E., Muirhead, C., Newbury-Birch, D., Waqas, M. & Kaner, E. (2018) Alcohol Screening and Brief Intervention in Police Custody Suites: Pilot Cluster Randomised Controlled Trial (AcCePT). Alcohol and Alcoholism. [Online] (agy039). https://www.ncbi.nlm.nih.gov/pubmed/29889245
|© Springer Nature|
Bates, S., Holmes, J., Gavens, L., De Matos, E. G., Li, J., Ward, B., Hooper, L., Dixon, S. & Buykx, P. (2018) Awareness of alcohol as a risk factor for cancer is associated with public support for alcohol policies. BMC Public Health. [Online] 18 (1),
Bermejo, I., Ren, S., Simpson, E., Clowes, M., Scott, D. L., Young, A. & Stevenson, M. (2018) Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Pharmacoeconomics. [Online] Available from: https://www.ncbi.nlm.nih.gov/pubmed/29882210.
Devlin, N., Brazier, J., Pickard, A. S. & Stolk, E. (2018) 3L, 5L, What the L? A NICE Conundrum. PharmacoEconomics. [Online] 36637–640.
Fuller, G. W., Goodacre, S., Keating, S., Perkins, G., Ward, M., Rosser, A., Gunson, I., Miller, J., Bradburn, M., Thokala, P., Harris, T., Carson, A., Marsh, M. & Cooper, C. (2018) The ACUTE (Ambulance CPAP: Use, Treatment effect and economics) feasibility study: a pilot randomised controlled trial of prehospital CPAP for acute respiratory failure. Pilot and Feasibility Studies. [Online] 4 (1), .
Gray, L. A., Wailoo, A. & Hernandez, M. (n.d.) Mapping the FACT-B instrument to EQ-5D-3L in Patients with Breast Cancer using Adjusted Limited Dependent Variable Mixture Models vs Response Mapping. Value in Health. http://eprints.whiterose.ac.uk/131975/
Hernandez-Villafuerte, K., Fischer, A. & Latimer, N. R. (n.d.) Challenges and Methodologies Using Progression Free Survival As A Surrogate For Overall Survival In Oncology. International Journal of Technology Assessment in Health Care. http://eprints.whiterose.ac.uk/130810/
Keetharuth, D., Taylor Buck, E., Acquadro, C., Conway, K., Connell, J., Barkham, M., Carlton, J., Ricketts, T. N., Barber, R. & Brazier, J. E. (n.d.) Integrating qualitative and quantitative data in the development of outcome measures: the case of the Recovering Quality of Life (ReQoL) measures in mental health populations. International Journal of Environmental Research and Public Health. (Special Issue ‘Mental Health and Social Care and Social Interventions’), . https://www.ncbi.nlm.nih.gov/pubmed/29949892
Kharroubi, S. & Rowen, D. L. (n.d.) Valuation of preference-based measures: Can existing preference data be used to select a smaller sample of health states? The European Journal of Health Economics. https://www.ncbi.nlm.nih.gov/pubmed/29980950
Lawton, K., Royals, K., Carson-Chahhoud, K. V, Campbell, F. & Smith, B. J. (2018) Nurse-led versus doctor-led care for bronchiectasis. Cochrane Database of Systematic Reviews. [Online] 2018 (6), . https://www.ncbi.nlm.nih.gov/pubmed/29926473
Pennington, R. M., Collins, B., Leigh, S., Martin, A. P., Owen, L., Fischer, A., Sumnall, H. & Bates, G. (2018) The cost-effectiveness of seven behavioural interventions to prevent drug misuse in vulnerable populations. International Journal of Drug Policy. [Online] 5742–50. Available from: https://www.sciencedirect.com/science/article/pii/S0955395918300987
Rowen, D. L., Labeit, A., Stevens, K., Elliot, J., Mulhern, B., Carlton, J., Basarir, H. & Brazier, J. (n.d.) Estimating a preference-based single index measuring the quality of life impact of self-management for diabetes. Medical Decision Making. https://www.ncbi.nlm.nih.gov/pubmed/29957107
Stevens, J. W. (n.d.) Using evidence from randomised controlled trials in economic models: What information is relevant and is there a minimum amount of sample data required to make decisions? PharmacoEconomics. https://www.ncbi.nlm.nih.gov/pubmed/29926358
Tappenden, P., Carroll, C., Stevens, J., Simpson, E., Thokala, P., Wong, R., Wright, J. & Auer, R. (2018) Ibrutinib for Treating Waldenström’s Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. [Online] 1–12. https://www.ncbi.nlm.nih.gov/pubmed/29951793
Tes, D., Kratkiewicz, K., Aber, A., Horton, L., Zafar, M., Arafat, N., Fatima, A. & Avanaki, M. R. N. (2018) Development and Optimization of a Fluorescent Imaging System to Detect Amyloid-β Proteins: Phantom Study. Biomedical Engineering and Computational Biology. [Online] 9117959721878108–117959721878108. https://www.ncbi.nlm.nih.gov/pubmed/29977121
Tuesday, 10 July 2018
|Dr Chris Carroll|
Dr Carroll said: "I look forward to working with Phil and the rest of the section's management team".
Dr Carroll joined ScHARR in 2004 and was appointed as a Research Fellow in 2007. In early 2011 he was appointed Senior Lecturer in Health Technology Assessment (HTA) and Course Director of the MSc in International Health Technology Assessment, Pricing and Reimbursement (iHTA). In 2014 Dr Carroll was promoted to Reader and made a University Senate Fellow for Excellence in Learning and Teaching.
Dr Carroll stepped down as Course Director of the iHTA programme in mid-2015 and returned to working for the ScHARR Technology Assessment Group (TAG) conducting appraisals for NICE. Since 2017 he has also been the Lead for the systematic reviewers in HEDS.
Friday, 6 July 2018
Our own Dr Nick Latimer created a series of animations on the topic of Economic evaluation in health care. The series of five videos have been very popular on his Youtube Channel can be viewed below and on our ScHARR Library YouTube Channel.
Wednesday, 4 July 2018
Dr Matt Franklin announced as our new Director of our Masters in Health Economics and Decision Modelling (HEDM)
|Dr Matt Franklin|
Dr Matt Franklin has taken over as Director of our Masters in Health Economics and Decision Modelling (HEDM).
The MSc in Health Economics and Decision Modelling (HEDM) is one of a suite of 3 MSc's that the University of Sheffield offer in the field of health economics, decision modelling and health technology assessment (HTA), the others being the on-line MSc in International Health Technology Assessment, Pricing and Reimbursement and the more econometrics-focused MSc in Economics and Health Economics.
"I remember my time as a Masters student at the University of Sheffield and I hope to use this experience to my advantage. I will be looking to apply my 10 years of health economic experience in an alumni, research, and teaching capacity to the Director of HEDM role. If I can serve the staff and students associated with the HEDM course as well as those associated with the E&HE course served me as a student 10 years ago, this is the best for which I could hope."
Tuesday, 3 July 2018
….is complete. The website lists reviews and protocols. Of note are……
- Botulinum toxins for the prevention of migraine in adults
- Workplace interventions for reducing sitting at work
- Parenteral opioids for maternal pain management in labour
- Interleukin inhibitors for psoriatic arthritis
- Stem cell therapy for multiple sclerosis
- Paracetamol, NSAIDS and opioid analgesics for chronic low back pain: a network meta‐analysis
Monday, 2 July 2018
CRC risk scores to improve efficiency of screening programme
Sponsor: Bowel Cancer UK - starting 1st July 2018
Sponsor: Bowel Cancer UK - starting 1st July 2018
Survival from colorectal cancer (CRC) is strongly related to stage at diagnosis. There is overwhelming evidence that national screening programmes reduce incidence and mortality. Stratified screening could potentially provide a way of improving the efficiency of screening by targeting limited resources to those at highest risk. We have previously published a systematic review of risk prediction models for CRC and externally validated those including phenotypic variables in UK Biobank.
To assess the potential impact of introducing risk stratification using phenotypic or genomic information into the current English bowel screening programme.
The research includes three Work Packages (WP): WP1- An update of our previous systematic review to identify risk models which include genomic information to predict the future incidence of colorectal cancer; WP2- External validation of the risk models identified in WP1 in the UK Biobank cohort; and WP3- Impact and cost-effectiveness analysis to model the potential for population health and impact on the health service if risk stratification using the best performing phenotypic or genomic risk model was introduced into the English bowel screening programme.
This work will inform decisions around future stratification of CRC screening programmes using both phenotypic and/or genomic information.